Therapy of myositis: Biological and physical

Current Opinion in Rheumatology

Volumn 26, Issue 6, 2014, Pages 704-711

  Lundberg, Ingrid E ^a   Vencovsky, Jiri ^b   Alexanderson, Helene ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

Author keywords

Biological treatment; Dermatomyositis; Exercise; Pharmacological treatment; Polymyositis

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SIFALIMUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

AEROBIC EXERCISE; ANTISYNTHETASE SYNDROME; DERMATOMYOSITIS; EXERCISE; HUMAN; INCLUSION BODY MYOSITIS; JUVENILE DERMATOMYOSITIS; MYOSITIS; PHYSIOTHERAPY; POLYMYOSITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANCE TRAINING; REVIEW; KINESIOTHERAPY; PROCEDURES; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; EXERCISE THERAPY; HUMANS; IMMUNOLOGIC FACTORS; MYOSITIS; TREATMENT OUTCOME;

EID: 84923067181     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000109     Document Type: Review

References (50)

1. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70:360-374.
2. Habers GE, Takken T. Safety and efficacy of exercise training in patients with an idiopathic inflammatory myopathy: a systematic review. Rheumatology (Oxford) 2011; 50:2113-2124.
3. Alexanderson H, Lundberg IE. Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies. Curr Opin Rheumatol 2012; 24:201-207.
4. Pachman LM, Liotta-Davis MR, Hong DK, et al. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum 2000; 43:2368-2377.
5. Aggarwal R, Oddis CV. Therapeutic advances in myositis. Curr Opin Rheumatol 2012; 24:635-641.
6. Chen D, Wang XB, Zhou Y, Zhu XC. Efficacy of infliximab in the treatment for dermatomyositis with acute interstitial pneumonia: a study of fourteen cases and literature review. Rheumatol Int 2013; 33:2455-2458.
7. Tosounidou S, MacDonald H, Situnayake D. Successful treatment of calcinosis with infliximab in a patient with systemic sclerosis/myositis overlap syndrome. Rheumatology (Oxford) 2014; 53:960-961.
8. Da Silva TC, Zon Pretti F, Shinjo SK. Adalimumab in antisynthetase syndrome. Joint Bone Spine 2013; 80:432.
9. Hengstman GJ, De Bleecker JL, Feist E, et al. Open-label trial of anti-TNFalpha in dermato-and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008; 59:159-163.
10. Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008; 67:1670-1677.
11. Brunasso AM, Aberer W, Massone C. New onset of dermatomyositis/polymyositis during anti-TNF-a therapies: a systematic literature review. Scientific World Journal 2014; 2014:179180.
12. Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013; 65:314-324.
13. Aggarwal R, Bandos A, Reed AM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 2014; 66:740-749.
14. Unger L, Kampf S, Lüthke K, et al. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. Rheumatology (Oxford) 2014. [Epub ahead of print]
15. Basnayake C, Cash K, Blumbergs P, et al. Use of rituximab in histologically confirmed idiopathic inflammatory myositis: a case series. Clin Rheumatol 2013. [Epub ahead of print]
16. Nalotto L, Iaccarino L, Zen M, et al. Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature. Immunol Res 2013; 56:362-370.
17. De Visser M. The efficacy of rituximab in refractory myositis: the jury is still out. Arthritis Rheum 2013; 65:303-306.
18. Zong M, Dorph C, Dastmalchi M, et al. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann Rheum Dis 2014; 73:913-920.
19. Kosmidis ML, Alexopoulos H, Tzioufas AG, Dalakas MC. The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study. J Neurol Sci 2013; 334:123-125.
20. Musuruana JL, Cavallasca JA. Abatacept for treatment of refractory polymyositis. Joint Bone Spine 2011; 78:431-432.
21. Arabshahi B, Silverman RA, Jones OY, Rider LG. Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr 2012; 160:520-522.
22. Kerola AM, Kauppi MJ. Abatacept as a successful therapy for myositis-a casebased review. Clin Rheumatol 2014. [Epub ahead of print]
23. Narazaki M, Hagihara K, Shima Y, et al. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford) 2011; 50:1344-1346.
24. Kondo M, Murakawa Y, Matsumura T, et al. A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis? Rheumatology (Oxford) 2014. [Epub ahead of print]
25. Higgs BW, Zhu W, Morehouse C, et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-a monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 2014; 73:256-262.
26. Guo X, Higgs BW, Rebelatto M, et al. Suppression of soluble T cell-associated proteins by an antiinterferon-a monoclonal antibody in adult patients with dermatomyositis or polymyositis. Rheumatology (Oxford) 2014; 53:686-695.
27. Wiesinger GF, Quittan M, Aringer M, et al. Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme. Br J Rheumatol 1998; 37:196-200.
28. Wiesinger GF, Quittan M, Graninger M, et al. Benefit of 6 months long-term physical training in polymyositis/dermatomyositis patients. Br J Rheumatol 1998; 37:1338-1342.
29. Johnson LG, Collier KE, Edwards DJ, et al. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. Clin Neuromusc Dis 2009; 10:178-184.
30. Bertolucci F, Neri R, Dalise S, et al. Abnormal lactate levels in patients with polymyositis and dermatomyositis: the benefits of a specific rehabilitative program. Eur J Phys Rehabil Med 2014; 50:161-169.
31. Alemo Munters L, Dastmalchi M, Andgren V, et al. Improvement in health and possible reduction in disease activity using endurance exercise in patients with established polymyositis and dermatomyositis: a multicenter randomized controlled trial with a 1-year open extension followup. Arthritis Care Res (Hoboken) 2013; 65:1959-1968.
32. Alemo Munters L, Dastmalchi M, Katz A, et al. Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis. Arthritis Res Ther 2013; 15:R83.
33. Riisager M, Mathiesen PR, Vissing J, et al. Aerobic training in persons who have recovered from juvenile dermatomyositis. Neuromuscul Dis 2013; 23:962-968.
34. Omori CH, Silva CA, Sallum AM, et al. Exercise training in juvenile dermatomyositis. Arthritis Care Res (Hoboken) 2012; 64:1186-1194.
35. Alexanderson H, Stenström CH, Jenner G, et al. The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand J Rheumatol 2000; 29:295-301.
36. Varjú C, PethöE, Kutas R, et al. The effect of physical exercise following acute disease exacerbation in patients with dermato/polymyositis. Clin Rehabil 2003; 17:83-87.
37. Escalante A, Miller L, Beardmore TD. Resistive exercise in the rehabilitation of polymyositis/dermatomyositis. J Rheumatol 1993; 20:1340-1344.
38. Alexanderson H, Munters LA, Dastmalchi M, et al. Resistive home exercise in patients with recent-onset polymyositis and dermatomyositis: a randomized controlled single-blinded study with a 2-year followup. J Rheumatol 2014; 41:1124-1132.
39. Mattar MA, Gualano B, Roschel H, et al. Exercise as an adjuvant treatment in persistent active polymyositis. J Clin Rheumatol 2014; 20:11-15.
40. Hejazi SM, Engkasan JP, Qomi MS. Intensive exercise and a patient in acute phase of polymyositis. J Back Musculoskelet Rehabil 2012; 25:231-234.
41. Hicks JE, Miller F, Plotz P, Chen TH, et al. Isometric exercise increases strength and does not produce sustained creatinine phosphokinase increases in a patient with polymyositis. J Rheumatol 1993; 20:1399-1401.
42. Alexanderson H, Stenström CH, Lundberg I. Safety of a home exercise programme in patients with polymyositis and dermatomyositis: a pilot study. Rheumatology (Oxford) 1999; 38:608-611.
43. HeikkiläS, Viitanen JV, Kautiainen H, et al. Rehabilitation in myositis: preliminary study. Physiotherapy 2001; 87:301-309.
44. Harris-Love MO. Safety and efficacy of submaximal eccentric strength training for a subject with polymyositis. Arthritis Rheum 2005; 53:471-474.
45. Alexanderson H, Dastmalchi M, Esbjörnsson-Liljedahl M, et al. Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis Rheum 2007; 57:768-777.
46. Chung YL, Alexanderson H, Pipitone N, et al. Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: six-month, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007; 57:694-702.
47. Regardt M, Schult ML, Axelsson Y, et al. Hand exercise intervention in patients with polymyositis and dermatomyositis: a pilot study. Musculoskeletal Care 2014. [Epub ahead of print]
48. Spector SA, Lemmer JT, Koffman BM, et al. Safety and efficacy of strength training in patients with sporadic inclusion body myositis. Muscle Nerve 1997; 20:1242-1248.
49. Arnardottir S, Alexanderson H, Lundberg IE, et al. Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J Rehabil Med 2003; 35:31-35.
50. Johnson GL, Edwards DJ, Walters S, et al. The effectiveness of an individualized, home-based functional exercise program for patients with sporadic inclusion body myositis. Clin Neuromusc Dis 2007; 8:187-194.